Budde et al. reported preliminary results employing autologous CD123 CAR-T cells in seven heavily pretreated R/R AML patients with the aim to obtain maximum disease reduction before a second allogeneic HCT, observing a CR in two patients, a morphologic response in one patient and a reduction of blast cells in two patients [62]. The gene discussed is IL3RA; the disease is acute myeloid leukemia.